LPTX

Leap Therapeutics, Inc. [LPTX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

LPTX Stock Summary

Top 10 Correlated ETFs

LPTX

Top 10 Correlated Stocks

LPTX

In the News

LPTX Financial details

Company Rating
-
Market Cap
82.94M
Income
-80.55M
Revenue
634K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
54
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-1.23
Forward P/E
-
PEG
-2.58
P/S
-
P/B
1.37
P/C
-
P/FCF
-2.01
Quick Ratio
7.38
Current Ratio
7.41
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-5.05
EPS next Y
-
EPS next Q
-
EPS this Y
-17.43%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-9.8%
-
-
-
-
SMA20
32.35%
SMA50
213.95%
SMA100
285.71%
Inst Own
-
Inst Trans
-
ROA
-97%
ROE
-132%
ROC
-1.2%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.235-10.2
52W High
-85.5%
52W Low
+45%
RSI
50.81
Rel Volume
2.63
Avg Volume
325.47K
Volume
855.73K
Perf Week
10.69%
Perf Month
215.9%
Perf Quarter
417.67%
Perf Half Y
232.65%
-
-
-
-
Beta
0.593
-
-
Volatility
0.18%, 0.81%
Prev Close
-8.23%
Price
1.45
Change
-5.84%

Something similar

Top by Market Cap
VTI
LLY
NVD.DE
BRK-A
BRH.DE
Top Correlated ETFs
SCC
MATH
Top Correlated Stocks
2540.T
5706.T
PYYX
2349.HK
ABBV
Similar Market Cap
AE
OCAX
0022.HK
6182.HK
LFGP

Company Profile

Healthcare Biotechnology
  • Volume Average 325.47K
  • Market Capitalization 82.94M
  • Employee 54
  • CEO Mr. Douglas E. Onsi J.D.
  • Headquarters Cambridge,MA,US
  • IPO Date 2017-01-25
  • Website https://www.leaptx.com

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.